Asset Details
Do you wish to reserve the book?
Immunological Markers Associated with Skin Manifestations of EGPA
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunological Markers Associated with Skin Manifestations of EGPA
Do you wish to request the book?
Immunological Markers Associated with Skin Manifestations of EGPA
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunological Markers Associated with Skin Manifestations of EGPA
2025
Overview
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis with eosinophilic inflammation and variable clinical presentations. Although skin manifestations are frequent, current classification criteria do not include them, which may underestimate their diagnostic value. This prospective observational study aimed to assess systemic and skin involvement as well as eosinophilia, anti-neutrophil cytoplasmic antibody (ANCA), and Anti-nuclear antibodies (ANA) serum levels in 20 EGPA patients followed for one year at the University Hospital of Messina, Italy, before starting Mepolizumab, 300 mg. Eosinophilia, ANCA status, systemic and skin involvement were also evaluated at 6 and 12 months; a literature review on these data supplements our findings. Skin involvement was present in 55% of patients, including purpura, urticarial vasculitis, angioedema, maculopapular rash, and nodules, mostly in ANCA-negative patients, though purpura was more frequent in ANCA-positive cases but without any statistically significant correlation. ANAs were present in 50% of patients, together with ANCA in two subjects and without in eight. Mepolizumab significantly reduced eosinophil levels, BVASs, and corticosteroid dependence, with notable improvement in skin symptoms. In conclusion, skin manifestations are common in EGPA and may represent useful indicators of disease activity. Their integration with ANCA status, eosinophil counts, and positivity to other autoantibodies could enhance diagnostic and monitoring strategies identifying different clusters of EGPA patients even if the small sample size limits the generalizability of the findings.
Publisher
MDPI AG,MDPI
Subject
/ Aged
/ Antibodies, Antineutrophil Cytoplasmic - blood
/ Antibodies, Antinuclear - blood
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asthma
/ Biopsy
/ Churg-Strauss Syndrome - blood
/ Churg-Strauss Syndrome - drug therapy
/ Churg-Strauss Syndrome - immunology
/ Churg-Strauss Syndrome - pathology
/ Female
/ Granulomatosis with Polyangiitis - blood
/ Granulomatosis with Polyangiitis - drug therapy
/ Granulomatosis with Polyangiitis - immunology
/ Granulomatosis with Polyangiitis - pathology
/ Humans
/ Male
/ Patients
/ Purpura
